Selective induction of apoptosis by leptomycin B in keratinocytes expressing HPV oncogenes

International Journal of Cancer

Volumn 120, Issue 11, 2007, Pages 2317-2324

  Gray, Lindsey J ^a   Bjelogrlic, Predrag ^a   Appleyard, Virginia C L ^b   Thompson, Alastair M ^b   Jolly, Carol E ^a   Lain, Sonia ^b   Herrington, C Simon ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Apoptosis; Human papillomavirus; Keratinocytes; Leptomycin B; Oncogenes

Indexed keywords

LEPTOMYCIN B; PROTEIN E6; PROTEIN E7; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL CULTURE; CELL CYCLE REGULATION; CELL NUCLEUS MEMBRANE; CONTROLLED STUDY; CULTURE MEDIUM; CULTURE TECHNIQUE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MONOLAYER CULTURE; MOUSE; NONHUMAN; ORGANOTYPIC RAFT CULTURE; PRIORITY JOURNAL; PROTEIN TRANSPORT; TOXICITY TESTING; UTERINE CERVIX CARCINOMA; VIRUS ONCOGENE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELLS, CULTURED; FATTY ACIDS, UNSATURATED; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINOCYTES; ONCOGENES; PAPILLOMAVIRIDAE;

EID: 34247394918     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22591     Document Type: Article

References (43)

1. Hamamoto T, Gunji S, Tsuji H, Beppu T. Leptomycins A and B, new antifungal antibiotics, part I: taxonomy of the producing strain and their fermentation, purification and characterization. J Antibiot (Tokyo) 1983;36:639-45.
2. Kudo N, Matsumori N, Taoka H, Fujiwara D, Schreiner EP, Wolff B, Yoshida M, Horinouchi S. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci USA 1999;96:9112-17.
3. Meissner T, Krause E, Vinkemeier U. Ratjadone and leptomycin B block CRM1-dependent nuclear export by identical mechanisms. FEBS Lett 2004;576:27-30.
4. Lain S, Xirodimas D, Lane DP. Accumulating active p53 in the nucleus by inhibition of nuclear export: a novel strategy to promote the p53 tumor suppressor function. Exp Cell Res 1999;253:315-24.
5. Smart P, Lane EB, Lane DP, Midgley C, Vojtesek B, Lain S. Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. Oncogene 1999;18:7378-86.
6. Hietanen S, Lain S, Krausz E, Blattner C, Lane DP. Activation of p53 in cervical carcinoma cells by small molecules. Proc Natl Acad Sci USA 2000;97:8501-6.
7. Lecane PS, Kiviharju TM, Sellers RG, Peehl DM. Leptomycin B stabilizes and activates p53 in primary prostatic epithelial cells and induces apoptosis in the LNCaP cell line. Prostate 2003;54:258-67.
8. Yoshida M, Nishikawa M, Nishi K, Abe K, Horinouchi S, Beppu T. Effects of leptomycin B on the cell cycle of fibroblasts and fission yeast cells. Exp Cell Res 1990;187:150-6.
9. Lain S, Midgley C, Sparks A, Lane EB, Lane DP. An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs. Exp Cell Res 1999;248:457-72.
10. Roberts BJ, Hamelehle KL, Sebolt JS, Leopold WR. In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721). Cancer Chemother Pharmacol 1986;16:95-101.
11. Newlands ES, Rustin GJ, Brampton MH. Phase I trial of elactocin. Br J Cancer 1996;74:648-9.
12. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
13. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
14. zur Hausen H. Papillomavirus infections - a major cause of human cancers. Biochim Biophys Acta 1996;1288:F55-F78.
15. Finzer P, Aguilar-Lemarroy A, Rosi F. The role of human papillomavirus oncoproteins E6 and E7 in apoptosis. Cancer Lett 2002;188:15-24.
16. Choo KB, Pan CC, Han SH. Integration of human papillomavirus type 16 into cellular DNA of cervical carcinoma: preferential deletion of the E2 gene and invariable retention of the long control region and the E6/E7 open reading frames. Virology 1987;161:259-61.
17. Wentzensen N, Vinokurova S, von Knebel Doeberitz M. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res 2004;64:3878-84.
18. Lane DP, Lain S Therapeutic exploitation of the p53 pathway. Trends Mol Med 2002;8:S38-S42.
19. Park DJ, Wilczynski SP, Paquette RL, Miller CW, Koeffler HP. p53 mutations in HPV-negative cervical carcinoma. Oncogene 1994;9: 205-10.
20. Gray L, Jolly C, Herrington CS. Human papillomaviruses and their effects on cell cycle control and apoptosis. In: Digard P, Nash AA, Randall RE, eds. Society for general microbiology symposium 64: molecular pathogenesis of virus infectionsed. Cambridge: Cambridge University Press, 2005. 235-51.
21. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-36.
22. Munger K, Basile JR, Duensing S, Eichten A, Gonzalez SL, Grace M, Zacny VL. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 2001;20:7888-98.
23. Eichten A, Westfall M, Pietenpol JA, Munger K. Stabilization and functional impairment of the tumor suppressor p53 by the human papillomavirus type 16 E7 oncoprotein. Virology 2002;295:74-85.
24. Halbert CL, Demers GW, Galloway DA. The E6 and E7 genes of human papillomavirus type 6 have weak immortalizing activity in human epithelial cells. J Virol 1992;66:2125-34.
25. Southern SA, Lewis MH, Herrington CS. Induction of tetrasomy by human papillomavirus type 16 E7 protein is independent of pRb binding and disruption of differentiation. Br J Cancer 2004;90:1949-54.
26. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
27. Xirodimas D, Saville MK, Edling C, Lane DP, Lain S. Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo. Oncogene 2001;20:4972-83.
28. Fredersdorf S, Milne AW, Hall PA, Lu X. Characterization of a panel of novel anti-p21Waf1/Cip1 monoclonal antibodies and immunochemical analysis of p21Waf1/Cip1 expression in normal human tissues. Am J Pathol 1996;148:825-35.
29. Leers MP, Kolgen W, Bjorklund V, Bergman T, Tribbick G, Persson B, Bjorklund P, Ramaekers FC, Bjorklund B, Nap M, Jomvall H, Schutte B. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 1999;187:567-72.
30. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, Munday NA, Raju SM, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995;376:37-43.
31. Zwerschke W, Jansen-Durr P. Cell transformation by the E7 oncoprotein of human papillomavirus type 16: interactions with nuclear and cytoplasmic target proteins. Adv Cancer Res 2000;78:1-29.
32. Thomas M, Banks L. Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene 1998;17:2943-54.
33. Li B, Dou QP. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA 2000;97:3850-5.
34. Masson M, Hindelang C, Sibler AP, Schwalbach G, Trave G, Weiss E. Preferential nuclear localization of the human papillomavirus type 16 E6 oncoprotein in cervical carcinoma cells. J Gen Virol 2003;84:2099-104.
35. Stewart D, Ghosh A, Matlashewski G. Involvement of nuclear export in human papillomavirus type 18 E6-mediated ubiquitination and degradation of p53. J Virol 2005;79:8773-83.
36. Freedman DA, Levine AJ. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol 1998;18:7288-93.
37. Storey A, Osborn K, Crawford L. Co-transformation by human papillomavirus types 6 and 11. J Gen Virol 1990;71(Pt 1):165-71.
38. Barbosa MS, Vass WC, Lowy DR, Schiller JT. In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential. J Virol 1991;65:292-8.
39. Barbosa MS, Edmonds C, Fisher C, Schiller JT, Lowy DR, Vousden KH. The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J 1990;9:153-60.
40. Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 1989;8:4099-105.
41. Li X, Coffino P. High-risk human papillomavirus E6 protein has two distinct binding sites within p53. of which only one determines degradation. J Virol 1996;70:4509-16.
42. Alani RM, Munger K. Human papillomaviruses and associated malignancies. J Clin Oncol 1998;16:330-7.
43. Bernard HU, Calleja-Macias IE, Dunn ST. Genome variation of human papillomavirus types: phylogenetic and medical implications. Int J Cancer 2006;118:1071-6.